Exelixis Q2 2025: total rev $568M, GAAP EPS $0.65; CABOMETYX NET launch, positive STELLAR-303

EXELIXIS, INC.

2025-Q2 EPS reported $1.20 revenue$1,123,708,000

Total revenues $568.3M; product revenues $520.0M (+19% YoY); collaboration rev $48.2M (down $151M due to prior-year Ipsen milestone).
GAAP net income $184.8M ($0.65 diluted EPS); non-GAAP net income $212.6M ($0.75 diluted EPS).
CABOMETYX launch in advanced NET capturing leading share, representing ~4% of Q2 CABOMETYX business.
Positive topline results from zanzalintinib STELLAR-303 study in colorectal cancer; plan to file for approval.
Early pipeline advancing: phase 1 trials for XL309, XB010, XB628; XB371 entering clinic.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.